This company listing is no longer active
HAEMATO Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Patrick Brenske
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 2.3yrs |
CEO ownership | n/a |
Management average tenure | no data |
Board average tenure | 11yrs |
Recent management updates
Recent updates
What Is HAEMATO AG's (ETR:HAEK) Share Price Doing?
Feb 22Potential Upside For HAEMATO AG (ETR:HAEK) Not Without Risk
Jan 04The Returns At HAEMATO (ETR:HAEK) Aren't Growing
Sep 12HAEMATO's (ETR:HAEK) Dividend Will Be Increased To €1.20
May 20We Like These Underlying Return On Capital Trends At HAEMATO (ETR:HAEK)
May 12HAEMATO's (ETR:HAEK) Returns On Capital Are Heading Higher
Dec 08The Strong Earnings Posted By HAEMATO (ETR:HAEK) Are A Good Indication Of The Strength Of The Business
May 24HAEMATO (ETR:HAEK) Hasn't Managed To Accelerate Its Returns
Nov 17HAEMATO (ETR:HAEK) Will Be Hoping To Turn Its Returns On Capital Around
May 30We're Not Very Worried About HAEMATO's (ETR:HAEK) Cash Burn Rate
Mar 08What Do The Returns At HAEMATO (ETR:HAEK) Mean Going Forward?
Feb 15Estimating The Fair Value Of HAEMATO AG (ETR:HAEK)
Jan 25Is Now An Opportune Moment To Examine HAEMATO AG (ETR:HAEK)?
Jan 04Reflecting on HAEMATO's (ETR:HAEK) Share Price Returns Over The Last Three Years
Dec 14CEO
Patrick Brenske
2.3yrs
Tenure
Mr. Patrick Brenske has been Chief Executive Officer of MPH Health Care AG (formerly known as MPH Mittelständische Pharma Holding AG) since January 23, 2009 and has been its Member of Management Board sinc...
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Deputy Chairwoman of the Supervisory Board | 16.4yrs | no data | no data | |
Chairwoman of the Supervisory Board | 11yrs | no data | no data | |
Member of Supervisory Board | 3.2yrs | no data | no data |
11.0yrs
Average Tenure
Experienced Board: HAEK's board of directors are seasoned and experienced ( 11 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/05/28 19:06 |
End of Day Share Price | 2024/02/29 00:00 |
Earnings | 2023/06/30 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HAEMATO AG is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Edward Acklin | First Berlin Equity Research GmbH |
Cosmin Filker | GBC AG |
Christian Ehmann | Warburg Research GmbH |